ETX 1153

Drug Profile

ETX 1153

Alternative Names: Amersib; Clostriban; eTS1153; ETX1153; ETX1153a; ETX1153b; ETX1153c; Mersanex; miconazole + nisin

Latest Information Update: 09 Dec 2014

Price : $50

At a glance

  • Originator e-Therapeutics
  • Developer e-Therapeutics; Khandelwal Laboratories
  • Class Antibacterials; Small molecules
  • Mechanism of Action 14-alpha demethylase inhibitors; Cell membrane modulators; Cholesterol synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Methicillin-resistant Staphylococcus aureus infections
  • Discontinued Clostridium infections

Most Recent Events

  • 16 Sep 2014 e-Therapeutics is looking for funding for ETX 1153c to resume development for Clostridium infections
  • 23 May 2014 ETX 1153 is available for licensing as of 23 May 2014. http://www.etherapeutics.co.uk/
  • 31 Jul 2013 Discontinued - Preclinical for Clostridium infections in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top